{"name":"Imprimis Pharmaceuticals, Inc.","slug":"imprimis-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":272303000,"revenueGrowth":36.4,"grossMargin":75.1,"rdSpend":20940000,"netIncome":-5139000,"cash":72927000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Topical Ketoprofen 10% Cream","genericName":"Topical Ketoprofen 10% Cream","slug":"topical-ketoprofen-10-cream","indication":"Topical treatment of musculoskeletal pain and inflammation","status":"phase_3"}]}],"pipeline":[{"name":"Topical Ketoprofen 10% Cream","genericName":"Topical Ketoprofen 10% Cream","slug":"topical-ketoprofen-10-cream","phase":"phase_3","mechanism":"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.","indications":["Topical treatment of musculoskeletal pain and inflammation","Localized joint and soft tissue pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPZFBMekJPMHNUaUZINEtqSFNfdmxLN05uX0tDcmx6U0NVRGZjQ29aY2FscVZiSTc4a0YyakV5V0xpdlpCdzB3c0xjVFE2aFpEQ1Y0ajl4TW5ETHo5MV9lUGt2WkI2a09HUHpVa0l0Si1nYlZUam1rZ054cFFvTGF0NzNzNTV2MGtGMzhYV0N0TzlGV0h3em1iRjVMTUExaHc?oc=5","date":"2026-03-17","type":"pipeline","source":"Finimize","summary":"Harrow: why this fast-growing eye-care pharma stock is worth a look - Finimize","headline":"Harrow: why this fast-growing eye-care pharma stock is worth a look","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPcm9Mc3B6OHI2NUZZY3BVZ1ZHd0xqOEs1dl9CclJMX3h5RGpEUER6VFIwSHpLRkx6M3VlYjg4bkpnLWRURDV1eVliTlh2Ums4WEMyOXFDZW91TTZOV3VXNm5uRHBXSW10MDUxS2xRNS1tUHU4UGFMVmQxVDNhQ2E4eUFiRjRrSHJFb0R5YWpraFpnRVJnZzdCYUZ0TWhjZkhwQkZpNkJNSjc0TllFN0R5ZTJn?oc=5","date":"2025-10-09","type":"pipeline","source":"The Capitol Forum","summary":"Harrow Shakes Up Imprimis Leadership Following Accusation from CA Board of Pharmacy - The Capitol Forum","headline":"Harrow Shakes Up Imprimis Leadership Following Accusation from CA Board of Pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQZ2U0MGdZVG90SWhzTEVQdVFYcGM1YU16MUdRYmdCMGQ2WkY3V3dIV1pUcVF4VDE5c1VIcGlHaXFZRnJTakNsamxBTU5fSTlwcjRRTVdXT2YxSFFsTzVoUEFlRm0tcGowSTktalpBdWJMS0pPazIwbHRIaUgtWEVTby12ZHhCamE4cUQxaEpiTHRYcWdCMGlLLVdoRjdlMXltQ3VtMER2ak1zY0YwN2Q0c2JEMkg3OEFVQjgzT3YzX3Q0clFySldyTkVpQ2Y2akU?oc=5","date":"2025-04-10","type":"pipeline","source":"Business Wire","summary":"Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire","headline":"Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxObWw0eW4ycmRlRDM4RmpsdW05dU8yR2dZdThsMnJ2TERldjRPQUJ0M1J0Q20wY2RVWXU1bUVuc0dyMENyYTBNaFNvNHR4Mmd4MTBmQndBQTctVXRUS21DUXRhRXlaZ1pPLTE1NWxpeTBDeE00Y1l3MFZoSERkQkM4ZEVjR1E2el9kblFyMksxZHZqR3JfYzJ5c3BKSmwwS29vNkRIU1Uxb2dIeEk3Rmc?oc=5","date":"2019-07-07","type":"pipeline","source":"The Tennessean","summary":"Harrow Health CEO took on Martin Shkreli before moving company to Nashville - The Tennessean","headline":"Harrow Health CEO took on Martin Shkreli before moving company to Nashville","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNT3BfYnVTcXBjbDJDelBFaHhtNXhHeFNnWk1LVjRCU0lzN29oQWpEZlFuN3V5dFVZS0pXNU1XaGdDQ3hmZG5EXzVSOTJzMVZEdUh1QW1MT29YLWtialdBZ3Rpb0ZIQkJqZHZXR29yNV9EeTd6OThfdUZpUEc4Sl93c21WX3RJdXJ5MDUzNGhBWkNmUndMbDJTeUZBYUd1UmVEaDVkbThOWFFpNHpMLVBaelMxOTd2YldpbTk0VHVHODBpandIdDdBWDFOZzN2RlAyb2tZLXpyQk5WTUU?oc=5","date":"2018-12-31","type":"pipeline","source":"GlobeNewswire","summary":"Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. - GlobeNewswire","headline":"Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":272303000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":272303000,"period":"2025-12-31"},{"value":199614000,"period":"2024-12-31"},{"value":130193000,"period":"2023-12-31"},{"value":88595000,"period":"2022-12-31"},{"value":72476000,"period":"2021-12-31"},{"value":48871000,"period":"2020-12-31"}],"grossProfit":204369000,"grossProfitHistory":[],"rdSpend":20940000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5139000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":72927000,"cashHistory":[],"totalAssets":399482000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}